New Delhi: After Hetero and Cipla, another pharmaceutical major Mylan was given permission by India’s drug regulator on Thursday to manufacture and market the anti-viral drug remdesivir for “restricted emergency use” on hospitalised COVID-19 patients, official sources said. Written informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting of serious adverse events have to be submitted.
On June 21, Hetero and Cipla were given permission to manufacture and market the drug on the same conditions. The Union Health ministry in its ‘Clinical Management Protocols for COVID-19‘ recommended the use of the drug in COVID-19 patients with moderate stages of the illness (those on oxygen support).
The drug has been included as an “investigational therapy” only for restricted emergency use purposes. It is not recommended for those with severe renal impairment and high level of liver enzymes, pregnant and lactating women, and those below 12 years, the document stated.
The drug, administered in the form of an injection, should be given at a dose of 200 mg on day one followed by 100 mg daily for five days. “The approval was given by the CDSCO on Thursday,” an official source in the know of the developments told .
Mylan had already entered into non-exclusive licensing agreements with Gilead Sciences, which is the patent holder of the drug remdesivir. US pharma giant, Gilead Sciences, had applied to the Indian drug regulatory agency, Central Drugs Standard Control Organisation (CDSCO), for import and marketing of remdesivir on May 29.
After due deliberations, permission under emergency use authorisation was granted by Drug Controller General of India (DCGI) on June 1 in the interest of patient safety and obtaining further data.
On June 21, Hetero and Cipla were given permission to manufacture the drug. Besides, Jubilant, BDR and Dr Reddy’s Labs have also applied to CDSCO for permission to manufacture and market the drug in India and are still awaiting due permission.